How is antiviral treatment for hepatitis C administered? The following experts recommend antiviral therapy for special populations Patients with renal insufficiency simeprevir, daclatasvir and ritonavir boosted paritaprevir, ombitasvir and dasabuvir are metabolized in the liver and can be used in patients with combined renal insufficiency, while eGFR <30 ml/min/1.73m2 and patients with end-stage renal disease there is currently no evidence for the use of sofobuvir. dAA regimens are available for 12 weeks in patients without cirrhosis and 24 weeks in patients with cirrhosis. peg-IFNα in combination with RBV should be dose adjusted according to eGFR. Liver transplant patients Antiviral therapy should be initiated at least 30 days prior to liver transplantation to prevent HCV reinfection after transplantation. sofobuvir+RBV (genotype 2), sofobuvir+ledipasvir (genotypes 1, 4, 5, 6) or sofobuvir+daclatasvir+RBV (all genotypes) Relapse or reinfection after liver transplantation Patients First choice of sofobuvir+RBV or sofobuvir+ledipasvir or sofobuvir+daclatasvir+RBV for 12 weeks. Patients who have had liver transplantation for more than 3 months can also have PEG-IFNα+RBV for 24-48 weeks or PEG-IFNα+sofobuvir+RBV for 12 weeks. Compensated cirrhosis (Child-Pugh class A) Standard dose PEG-IFNα combined with RBV for 48-72 weeks, PEG-IFNα+sofobuvir+RBV for 12-24 weeks, and sofobuvir+daclatasvir for 12-24 weeks, depending on the genotype, are applied. The treatment regimen without IFN is preferentially recommended. Liver ultrasound is still required every 6 months to monitor HCC in all cirrhotic patients after obtaining SVR. Decompensated cirrhosis (Child-Pugh class B/C) Choose IFN-free and RBV-free regimens for all genotypes. sofobuvir+daclatasvir for 24 weeks; sofobuvir+ledipasvir for 24 weeks for genotypes 1, 4, 5 and 6 and 16-20 weeks for genotype 2/3. IFN-based therapy is contraindicated, and paritaprevir, ombitasvir combination is contraindicated in decompensated cirrhosis. No other DAA requires dose adjustment.